FDA Grants Approval to Roche’s Susvimo for Treatment of Diabetic Retinopathy
FDA Approves Roche’s Susvimo as the First and Only Continuous-Delivery Treatment for Diabetic Retinopathy, Offering Nine-Month Dosing Durability In a significant advancement for patients suffering from diabetic retinopathy (DR), the…
Lilly’s Kisunla Approved in Australia for Early Alzheimer’s Treatment
Lilly’s Kisunla (Donanemab) Gains Marketing Authorization in Australia for Early Alzheimer’s Treatment Eli Lilly and Company has announced that the Australian Therapeutic Goods Administration (TGA) has granted marketing authorization for…
Addressing Barriers: An Open Letter on Obesity Care and Insurance Access
A Call for Change: Ensuring Access and Insurance Coverage for People Living with Obesity In recent months, abrupt changes to insurance coverage for obesity management medications have placed thousands of…
AstraZeneca Marks 7th Year of ASCO Plenary Data, Advancing Breast and Gastric Cancer Care
AstraZeneca Showcases Broad Oncology Leadership with More Than 80 Abstracts and Two Plenary Presentations at ASCO 2025, Reinforcing Ambition to Eliminate Cancer as a Cause of Death AstraZeneca is poised…
Sanofi to Acquire Vigil Neuroscience, Boosting Alzheimer’s Drug Pipeline
Sanofi to Acquire Vigil Neuroscience in $470 Million Deal, Bolstering Neurology Pipeline with Promising Alzheimer’s Drug Candidate In a strategic move that further solidifies its commitment to neurological disorders, Sanofi…
Merck Reports Positive Phase 2 Results for Enpatoran in Lupus Patients
Merck Unveils Positive Phase 2 Results for Enpatoran, Showing Significant Reduction in Disease Activity in Patients with Cutaneous and Systemic Lupus with Active Rash Merck, a global leader in science…
FDA Advisory Committee Declines to Support Genentech’s Columvi Expansion Proposal
Roche’s Genentech Faces Setback as FDA Advisory Committee Rejects Columvi Expansion Proposal The U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) delivered a significant blow to Genentech,…
FDA Grants Interchangeable Status to Celltrion’s YUFLYMA
Celltrion’s YUFLYMA® Secures Full FDA Interchangeability Status Across All Approved Forms and Strengths, Reinforcing Market Leadership and Commitment to Affordable Biologics Celltrion, Inc., a global biopharmaceutical company headquartered in South…
Grifols Gets FDA Nod for Phase 2 Trial of Eye Drops for Dry Eye Disease
Grifols Secures FDA Clearance to Advance Immunoglobulin Eye Drops into Phase 2 Trial for Dry Eye Disease Grifols, a global leader in the production of plasma-derived medicines and a prominent…
Analyzing the Economic and Commercial Drivers of Health in Small Island Developing States
Charting a Healthier Future: A Comprehensive Analysis of Economic and Commercial Determinants of Health in Small Island Developing States A newly released technical paper by the World Health Organization (WHO)…
Alnylam Releases 2024 Corporate Responsibility Report Highlighting ESG Progress
Alnylam Pharmaceuticals Unveils 2024 Corporate Responsibility Report, Showcasing Impact Across ESG Pillars Alnylam Pharmaceuticals, the industry leader in RNA interference (RNAi) therapeutics, has published its 2024 Corporate Responsibility Report, reaffirming…
BioNTech Strengthens UK Alliance to Enhance Regional R&D Initiatives
BioNTech Strengthens Partnership with UK Government to Significantly Expand Regional Research and Development Efforts BioNTech , a leading biotechnology firm recognized globally for its pioneering work in mRNA technology and…